REFERENCES
- Walter M, Thomas ED. Bone marrow transplantation for thalassemia. The USA experience. Am J Pediatr Hematol Oncol. 1994;16(1):11–17.
- Lucarelli G, Galimberti M, Giardini C, et al. Bone marrow transplantation in thalassemia: the experience of Pesaro. Ann N Y Acad Sci. 1998;850:270–275.
- Mentzer W, Cowan M. Bone marrow transplantation for beta-thalassemia: the University of California San Fransisco experience. J Pediatr Hematol Oncol. 2000;22(6):598–601.
- Pawlowska AB, Blazar BR, Angelucci E, Baronciani D, Shu XO, Bostrom B. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant. 1997;20(11):915–920.
- Chandy M, Balasubramanian P, Ramachandran SV, et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia–the role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant. 2005;36(10):839–845.
- Casper J, Knauf W, Kiefer T, et al. Treosulfan and Fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood. 2004;103(2):725–731.
- Manna M, Nesci S, Andreani M, Tonucci P, Lucarelli G. Influence of the conditioning regimens on the incidence of mixed chimerism in thalassemic transplanted patients. Bone Marrow Transplant. 1993;12(Suppl. 1):70–73.
- Bernardo ME, Zecca M, Piras E, et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Br J Haematol. 2008;143(4):548–551.
- Erer B, Angelucci E, Lucarelli G, et al. Hepatitis C virus infection in thalassemia patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994;14(3):369–372.
- Gaziev J, Sodani P, Lucarelli G, et al. Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft. Bone Marrow Transplant. 2008;42(6):397–404.